ISCT Hails Landmark US FDA Approval of RYONCIL as Major Milestone for MSC Field

VANCOUVER, BC, Dec. 20, 2024 /PRNewswire/ – The International Society for Cell & Gene Therapy (ISCT) celebrates the US Food and Drug Administration’s (FDA) landmark decision to approve Mesoblast Limited’s allogenic, bone marrow-derived mesenchymal stromal cell (MSC) product, RYONCIL®…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.